Journal
MOLECULAR PSYCHIATRY
Volume 23, Issue 5, Pages 1244-1250Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/mp.2017.25
Keywords
-
Funding
- Swedish Medical Research Council [2009-7053, 2013-2838, 523-2014-3467]
- Swedish Brain Foundation
- Ahlen-siftelsen
- Svenska Lakaresallskapet
- Petrus och Augusta Hedlunds Stiftelse
- Torsten Soderbergs Stiftelse
- AstraZeneca-Karolinska Institutet Joint Research Program in Translational Science
- Soderbergs Konigska Stiftelse
- Knut och Alice Wallenbergs stiftelse
- Stockholm County Council
- Karolinska Institutet
Ask authors/readers for more resources
Schizophrenia is characterized by a multiplicity of symptoms arising from almost all domains of mental function. gamma-Aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the brain and is increasingly recognized to have a significant role in the pathophysiology of the disorder. In the present study, cerebrospinal fluid (CSF) concentrations of GABA were analyzed in 41 first-episode psychosis (FEP) patients and 21 age- and sex-matched healthy volunteers by high-performance liquid chromatography. We found lower CSF GABA concentration in FEP patients compared with that in the healthy volunteers, a condition that was unrelated to antipsychotic and/or anxiolytic medication. Moreover, lower CSF GABA levels were associated with total and general score of Positive and Negative Syndrome Scale, illness severity and probably with a poor performance in a test of attention. This study offers clinical in vivo evidence for a potential role of GABA in early-stage schizophrenia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available